Fibrillatory Factor in Ventricular Tachycardia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01974908|
Recruitment Status : Unknown
Verified October 2013 by Jaswinder Gill, M.D., Guy's and St Thomas' NHS Foundation Trust.
Recruitment status was: Not yet recruiting
First Posted : November 4, 2013
Last Update Posted : November 4, 2013
This study involves recording electrical signals inside the heart during an ablation procedure. It is thought that by studying these electrical signals in detail the investigators may be able to better identify and treat patients at risk of Ventricular Tachycardia (VT).
VT is where the lower chambers (ventricles) of your heart beat fast and this condition can be life-threatening. An ablation procedure is performed in patients who have VT despite the best treatment available with tablets.
Cardiac ablation involves interrupting the abnormal electrical signals, which cause VT, by applying a type of electrical energy through a catheter. An important part of the ablation procedure is the identification of the exact part of the heart muscle responsible for causing the VT. This typically involves sampling the electrical signals in lots of different areas of the heart, which allows the construction of computer generated 3 dimensional pictures of the structure and the electrical circuits inside the ventricle. Recent research has identified a new method to interpret these electrical signals (called Fibrillatory Factor - FF), which may allow better identification of the area within the ventricle that should be ablated.
A standard VT ablation will often involve us controlling the heart-beat by pacing the heart through 1 of the investigators catheters within the heart. The electrical response to pacing at different heart rates can often provide your doctor with information to help the ablation. This study will involve an additional period of pacing at different heart rates, during which the electrical response is measured in different areas around the ventricle. This will allow us to calculate areas of the ventricle, which the investigators new measure FF would predict to be the source of the VT. In the future this may then allow us to better identify patients who are at risk of VT, and to better locate the area that needs to be ablated.
|Condition or disease||Intervention/treatment|
|Ventricular Tachycardia||Procedure: Fibrillatory Factor calculation (FF)|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Using Fibrillatory Factor to Predict the Source of Ventricular Tachycardia in Man|
|Study Start Date :||November 2013|
|Estimated Primary Completion Date :||November 2014|
U.S. FDA Resources
Experimental: Ventricular Tachycardia (VT)
Patients with VT will undergo a clinically indicated ablation of their VT
Procedure: Fibrillatory Factor calculation (FF)
During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
- Fibrillatory Factor [ Time Frame: 18 months ]To identify the proportion of clinical VT circuits which could be predicted during sinus rhythm from the calculation of fibrillation factor. The number of FF derived VT exit points which are successfully predicted blindly by the investigators (using the clinically derived VT exit point based on electrophysiology assessment and ablation) will be the primary endpoint.
- Real-time fibrillatory factor [ Time Frame: 18 months ]Having established that fibrillatory factor (FF) can predict VT circuits we will then develop our software further so that we can calculate FF in real-time. This will then be used in further research studies to guide invasive mapping.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01974908
|Contact: Jaswinder Gill, MD||+44 firstname.lastname@example.org|
|Contact: Nicholas Child, BM||+44 email@example.com|
|Guys and St Thomas' NHS Trust||Not yet recruiting|
|London, United Kingdom, SE1 7EH|
|Principal Investigator: Jaswinder Gill, MD|
|Principal Investigator:||Jaswinder Gill, MD||Guy's and St Thomas' NHS Trust|